Eton Pharmaceuticals Inc. (ETON) Misses Q1 EPS by 1c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q1 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.3 million.

As of March 31, 2024, the Company had cash and cash equivalents of $16.7 million and expects continued sales growth to result in positive operating cash flow throughout the remainder of 2024.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance